Our data demonstrate that in in vivo model of long‐term diabetic renal pathology, restoring high TIMP3 activity specifically in the kidney, may represent a therapeutic strategy for the amelioration of renal damage under conditions, including diabetic nephropathy, in which its reduction is related to the disease onset and progression. Here, TIMP3 is linked to diabetic kidney disease.